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Abstract
Tuberculosis (TB) remains a major killer amongst the infectious diseases. Current treatment involves a four-drug
regimen for at least 6 months. New drugs and regimens are required to shorten treatment duration, reduce toxicity
and combat drug resistance, but the optimal methodology to define the critical path for novel regimens is not well
defined. We undertook a systematic review to summarise outcomes reported in Phase II trials of patients with
newly diagnosed pulmonary TB to assess the need for a core outcome set. A systematic search of databases
(PubMed, MEDLINE, EMBASE and LILACs) was conducted on 1 May 2015 to retrieve relevant peer-reviewed articles.
Reference lists of included studies were also searched. This systematic review considered all reported outcomes.
Risk of bias was considered via sequence generation, allocation concealment, blinding, reasons for exclusions, and
selective reporting. Of 55 included studies, 20 were Phase IIB studies based on culture conversion, 32 were Phase
IIA studies based on quantitative bacteriology, and three considered alternative outcomes. Large variation in
reported outcomes and trial characteristics was observed across the included studies. Bacteriological results were as
often expressed in terms of positivity as negativity, with varying definitions of culture conversion. Variation in
reporting was particularly marked for Phase IIA studies, where multiple time intervals were typically selected for
analysis and sometimes resulted in differing interpretations of the efficacy of drugs or regimens. Within both Phase
IIA and IIB studies, there was variation in the time points at which the study participants were sampled, as well as in
the bacteriological media and methods used. For successful future meta-analysis of early-phase studies, the findings
of this review suggest that development of a core outcome set would be desirable. This would enable trial results
to be more easily compared and combined, potentially leading to more effective development of new treatment
strategies for patients with TB. Pending development of, and agreement on, such a core outcome set, we suggest
some interim recommendations for reporting of future phase II studies of pulmonary tuberculosis.
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Background
Treatment of tuberculosis (TB) has evolved very slowly
in the 40 years since current standard first-line regimens
were first developed. Combinations of up to four drugs
are needed for 6 months or more in order to ensure a
relapse-free cure for most patients. Screening novel
treatment regimens in Phase II trials is challenging be-
cause early indications of treatment efficacy rely on bac-
teriological biomarkers whose relation with long-term
outcomes is unclear. Furthermore, this information can
be obtained and expressed in a number of different
ways, leading to a lack of consistency and comparability
in the outcomes reported across clinical trials. These un-
certainties are a critical risk to decision-making about
which regimens should progress to Phase III trials,
which are large, prolonged and expensive.
Possible bacteriological outcomes in TB are diverse.
Mycobacterium tuberculosis may be grown on solid or li-
quid media of different types using different processing
and decontamination methods. The laboratory results
may be expressed as culture positivity at single time-
points, hazard of culture conversion over multiple time-
points, changes in or rate of elimination of counts of
colonies on solid media, and time-to-positivity in
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automated liquid culture systems. Furthermore, the
method of analysis may vary accordingly with the type of
endpoint from simple analysis of proportions to linear
or non-linear models of colony counts or liquid cultures
to time-to-event analysis of culture conversion. Typic-
ally, proof-of-concept Phase IIA studies utilise quantita-
tive bacteriology to study monotherapy over study
periods no longer than 14 days (‘early bactericidal activ-
ity’ or EBA), whereas Phase IIB studies of drug combina-
tions utilise a wider variety of methods over a longer
time period, usually the first 56 days of treatment with a
particular focus on culture conversion at 2 months,
which has historically correlated well with long-term
outcomes [1, 2]. Recently however Phase IIA studies of
combination regimens have become more common.
This diversity is potentially problematic in a thera-
peutic area in which there is relatively limited capability
to conduct large or multiple trials of the same regimen
and where the relationship of short to long term end-
points is incompletely understood. Without comparabil-
ity of outcomes across trials considering new regimens,
it may be challenging to synthesize evidence effectively
and draw the methodological conclusions necessary to
improve the conduct of future trials. These issues have
become pressing in light of recent prominent disap-
pointments in Phase III studies and with the emerging
need in the field to evaluate novel combinations of drugs
efficiently [3]. With this in mind, we systematically
reviewed the literature of Phase II studies in pulmonary
TB to determine how outcomes are currently defined,
how commonly they are used in published studies to
date, and how they are employed in the current drug de-
velopment pathway.
Review
Methods
Randomised controlled trials, or quasi-randomised trials,
were included in our systematic review of the available
literature. Included studies had to include patients with
smear- and culture-positive pulmonary tuberculosis that
were being treated for the first time, or had known iso-
niazid mono-resistant organisms on susceptibility test-
ing. Only trials including regimens containing any
combination of historic (rifampicin (R), isoniazid (H),
pyrazinamide (Z), ethambutol (E), thiacetazone (T),
para-aminosalicylic acid (P), and streptomycin (S)), or
novel drugs used or proposed for use in first-line treat-
ment regimens (rifabutin (Rb), rifapentine (Rp), levoflox-
acin (L), ofloxacin (O), gatifloxacin (G), moxifloxacin
(M), bedaquiline (J), and PA-824 (Pa)) were considered.
A systematic search of databases (PubMed, MEDLINE,
EMBASE and LILACs) was conducted on 1 May 2015
to retrieve relevant peer-reviewed articles. The employed
search strategy drew upon common phrases and terms
used in the literature. Keywords (appropriately truncated
to allow a wide search) were combined with medical
subject headings (MeSH) to comprehensively search four
databases. The PubMed inclusive search strategy was as
follows, with relevant modifications made as necessary
for the other databases:
1. Search (tuberculosis) AND clinical trials
2. Search ((((((((((((((rifampicin) OR isoniazid) OR
pyrazinamide) OR ethambutol) OR thiacetazone)
OR pyrazinamide) OR streptomycin) OR rifabutin)
OR rifapentine) OR levofloxacin) OR ofloxacin) OR
gatifloxacin) OR moxifloxacin) OR bedaquiline) OR
PA-824
3. Search (#1) AND #2
No language restrictions were imposed. The search
strategy was supplemented by hand searching reference
lists of included studies and relevant reviews. One au-
thor (GD) reviewed the title and available abstract for all
identified citations to determine relevance. Another au-
thor (LB) repeated this process on 1 May 2015 to check
for additional studies. Following the initial review, both
authors (LB and GD) independently reviewed full-text
publications to make a final selection of included Phase
II studies evaluating either monotherapy or combination
regimens. A structured form was used to record relevant
information and ensure uniformity of evaluation for each
study. Extracted data included study characteristics in-
cluding country of study, sample size, treatments
(including dosages and regimens), and all reported out-
comes. Risk of bias was considered via sequence gener-
ation, allocation concealment, blinding, reasons for
exclusions, and selective reporting.
Results
The flow of studies through the review is shown in Fig. 1.
The main reasons for exclusion were failure to meet the
inclusion criteria, and study design other than rando-
mised controlled trial. In total, 55 relevant studies were
identified and included.
A bar chart summarising the year of publication of the
included studies can be seen in Fig. 2. In 1996, CON-
SORT guidelines were first published for transparent
reporting of clinical trials [4]. The majority (79 %) of
studies included in our review were published after
1996, and consequently should conform to the CON-
SORT guidelines and present thorough information on
items such as trial design, intervention, participants, and
outcomes, which must be completely defined [4].
Despite the CONSORT guidelines, a core outcome
set for TB that defines a minimum set of clearly
defined outcomes to be reported in each future study
[5] has not yet been developed. Consequently, there is
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wide variation in the definition and type of outcomes
reported. Most studies included in our review re-
ported more than one outcome, and the distinction
between primary and secondary outcomes was often
unclear. Therefore all outcomes included in each
study have been considered and are summarised in
Table 1.
The methods and purposes of Phase IIA and IIB stud-
ies in tuberculosis differ, and we have considered these
study types separately in the quantitative review that
Assessed
(n = 611)
Included
(n = 55)
Excluded
(n = 557)
Addition studies identified
(n = 1)
Flow of studies in the review
Fig. 1 Flow of studies in the review
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Fig. 2 Year of publication of included studies
Bonnett and Davies Trials  (2015) 16:518 Page 3 of 9
follows. Of the 55 included studies, 32 were Phase IIA
studies, 20 were Phase IIB studies, and three were de-
signed to consider alternative outcomes such as contam-
ination [6], and Gaffky code - a numerical rating for the
classification of tuberculosis according to the number of
tubercle bacilli in the sputum [7]. One study considered
both Phase IIA and IIB outcomes [8].
In addition to the differing types of phase II studies,
different culture media were considered across trials. For
example, 34 studies (26 Phase IIA studies, five Phase IIB
studies, one study considering EBA and culture together
[8], and two that considered alternative outcomes [6, 9])
reported results obtained using solid media such as
Lowenstein-Jensen and Middlebrook 7H10. In 12 cases
(eight Phase IIB studies and four Phase IIA studies), the
laboratory methodology described the use of both solid
and liquid media, such as the BACTEC or MGIT system,
and a single set of results combined over the multiple
media were presented. Three studies (all Phase IIB
studies [10–12]) described culture on both liquid and
solid media but presented disaggregated results per
medium. Several studies did not describe the medium
used - one Phase IIA study [13], four Phase IIB studies
[14–17], and one study looking at an alternative out-
come [7]. Three of these studies were published pre-
CONSORT [7, 14, 15]. One study was a conference ab-
stract [13] where space constraints meant methodology
could not be reported, and two were published in Rus-
sian language journals, which appeared not to adopt the
CONSORT reporting guidelines [16, 17].
A range of analytic approaches to these varied data
were considered, with multiple and wide-ranging
methods being reported in most publications. Some au-
thors opted to analyse their data using regression
models such as logistic [12, 18] or linear [10, 19–21]
analysis. More commonly, authors considered t-tests
[6, 22, 23], ANOVA methodology [24–26], and chi-
squared tests [11, 18, 27] for normally distributed data,
or Kruskal-Wallis [28, 29], Mann-Whitney U [30, 31],
or equivalent tests when the data was not normally dis-
tributed. Infrequently, time-to-event analysis method-
ology was used [12, 28, 32], as well as correlation
methodology, including the Wilcoxon signed-rank test
[8, 30, 31]. None of the studies were adjusted for mul-
tiple comparisons.
Regarding risk of bias, 24 (44 %) studies did not report
the method of sequence generation. All but four studies
(83 %) used random allocation (with stratification in
some cases), rather than consecutive allocation. Only
four studies (7 %) mentioned allocation concealment,
mainly via opaque envelopes. Six studies (11 %) were of
a double-blind design, and another six were single-blind
studies. Twenty-eight studies (51 %) provided reasons
for exclusions, or numbers lost to follow-up. Seventeen
(31 %) studies were published pre-CONSORT when
selecting reporting was not considered as a possible
source of bias. In all studies published post-CONSORT,
the risk of bias is unclear, as there is insufficient infor-
mation to determine whether the published reports in-
clude all expected outcomes, including those that were
pre-specified.
Phase IIA studies
More than half (56 %) of the included studies were de-
signed to assess EBA, although authors did not always
precisely define this term and explicit definitions differed
between studies. In most cases, EBA was defined as the
fall, or mean rate of change, in log10 colony-forming
units (CFU) per ml sputum over various time periods or
between two time-points. Some authors did not define
Table 1 Reported outcomes
Outcome Definition No. studies reporting outcome
EBA Fall or rate of change in log10 CFU/ml sputum 36
CFU count Mean concentration of viable bacilli 11
AFB Acid-fast bacilli 3
Culture negativity Proportion, or time to, culture negativity 8
Culture positivity Proportion, or time to, culture positivity 10
Smear/culture conversion Proportion converting, or time to conversion 9
Sterilisation Proportion or time to sterilisation 2
Other culture outcome For example, persistence, relapse, time to detection, culture status 4
Adverse events 5
Gaffky code 1
Contamination Of cultures 1
Mortality 1
Symptom disappearance Proportion with, or time to symptom disappearance 1
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their outcome as EBA but used methods that conformed
to this approach, for example, decrease in sputum bacil-
lary load of Mycobacterium TB (M. TB) from pre-
treatment to day 15 of study drug treatment [33], or
mean rate of decline of CFU [20], or decrease in viable
count [34]. In one case, EBA was reported over 8 weeks
[8]. Figure 3 and Fig. 4 summarise the reported time
points in Phase IIA studies, showing that for the major-
ity of studies included in this review, endpoints were fo-
cused only on the first week of treatment.
EBA studies showed a range of durations from 2 to
90 days. Seven studies lasted 2 days, three lasted 7 days,
and seven lasted 14 days. Other frequent durations were
5 days (six studies), 28 days (three studies), and 15 days
(two studies). Infrequently chosen durations were 8, 9,
30, 56 and 90 days, each of which was used for individ-
ual studies only. EBA results were most frequently re-
ported in a table with differing time intervals from zero
to 14 days. Measures included EBA 2 to 14 days [35], 2
to 5 days [24], and 7 to 14 days [36], along with the
more common 0 to 2 days, 2 to 7 days and 0 to 7 days
[37]. In other studies, EBA was reported in a figure and
was therefore presented at a number of time points, for
example, once daily from days 0 to 5 [38] or, once daily
on days 0, 1, 2, 3, 4, 6, 8, 10, 12 and 14 [35].
Some authors referred to EBA specifically as the
change in log10 CFU/ml sputum during the first 2 days
of treatment and referred to ‘extended EBA’ as the de-
cline in bacilli during the last 5 days of study drug ad-
ministration (for example, days 2 to 7) [26, 29]. Several
studies, instead of reporting fall or change in log10 CFU/
ml, defined as EBA above, reported mean concentration
of viable bacilli at a fixed time point, or mean viable
count (log10 CFU/ml) [39]. CFU count was always pre-
sented in table form, and there was better agreement
among authors about the definition of this outcome.
However, in one case [40] the CFU counts were standar-
dised and in another the rate of fall of CFU counts was
reported (referred to as the ‘kill index’) [41]. The time
interval over which CFU counts were presented ranged
from 2 days to 56 days in one case [6].
Phase IIB studies
Within studies designed to consider 2-month outcomes,
the most frequently reported outcome (30 %) related to
culture positivity. This was measured in many ways in-
cluding time of last positive sputum culture or smear [9],
and time to stable culture conversion. This was defined as
the number of days from study treatment initiation to the
time of sputum collection yielding the first negative cul-
ture that was followed by at least one subsequent negative
culture and no subsequent positive culture [42]. In one
study, positivity was expressed as the percentage of cul-
tures positive at fixed time points such as at 28 days [39].
Regarding culture negativity, whilst most (24 %) authors
opted to present the proportion of negative cultures at a
time point (usually 2 months), some used time to [28], or
speed of [12], culture conversion. Negativity was more
simply expressed as either a binary outcome at a fixed
time point [27], or the proportion of patients whose cul-
ture had converted at a fixed time point [10, 42]. The def-
inition of time to culture conversion varied between
studies. One study defined time to culture conversion as
the time from the start of treatment to the first of two
consecutive culture negative sputum samples on non-
consecutive days that were not followed by a positive
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Fig. 3 Reported time points in Phase IIA studies - discrete quantitative bacteriological time points
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sputum sample [10]. Another defined the outcome as the
time point after which all sputum cultures were negative
[12]. All relevant studies presented results at 2 months,
but also additional time points where culture status was
considered (weekly, or biweekly from zero to 8 weeks [18,
27]). Figure 5 summarises the reported time points in
Phase IIB studies. Infrequently, studies reported culture
conversion over a range of days, for example, 0 to 2 days.
Notably, few studies clearly reported numbers of cul-
ture samples missing due to non-attendance, sample
contamination, or lack of sputum production at each
time point.
Trial characteristics
In addition to the diversity of the outcomes reported,
and the variation in their definitions, it should be noted
that there was also variation across trial characteristics.
As mentioned above, different time points were used for
the reporting of outcomes. This adds to the complica-
tion when attempting to compare the results from mul-
tiple studies to synthesize evidence to support treatment
regimens. Finally, in most cases an estimate of variability,
such as a standard deviation or 95 % confidence interval
was provided together with the point estimate. Some stud-
ies, however, only presented a point estimate (for example,
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[43]). These issues all make combining evidence from
multiple studies via meta-analysis challenging.
Conclusions
The results of this systematic review show that there is
large variation in the outcomes and trial characteristics
reported across phase II studies in pulmonary TB and in
the statistical methods used to analyse them. Within
both Phase IIA and IIB studies, there was variation in
the time points at which study participants were sam-
pled, as well as in the media used both in terms of the
use of solid versus liquid media, and in the specific
medium used, for example, Middlebrook 7H10 versus
7H11. Variation in reporting was particularly marked for
Phase IIA studies, where multiple, apparently arbitrary,
time intervals were typically selected for analysis, some-
times resulting in differing results and interpretations of
the efficacy of drugs or regimens. Recently, alternative
approaches have been proposed based on statistical
modelling, but there is no general consensus on which
approach should have priority. Phase IIB studies usually
collect bacteriological samples on a weekly or bi-weekly
basis. Bacteriological results were as often expressed in
terms of positivity as negativity, with varying definitions
of culture conversion. Though 2-month culture conver-
sion is often used as the primary endpoint in Phase IIB
studies, a number of different approaches have been used
to analyse data at prior time points, singly or together. In
general, logistic regression analyses of culture conversion
were more common than time-to-event approaches.
In recent years, automated liquid culture systems for
mycobacteria have become more widely distributed and
are increasingly used in clinical trials. Culture positivity
tends to persist for longer in such systems than on trad-
itional solid culture because of their inherently greater
sensitivity. While there are currently limited available
data to clearly define comparability across these different
methods, it seems likely that these technical differences
could contribute considerable additional variability to
any of the endpoints discussed here [12, 18, 27, 42]. It
may therefore be important to be able to distinguish be-
tween or disaggregate data derived from these different
laboratory methods.
Recently, efforts have been made to harmonize data
collection standards in tuberculosis trials [44] and to
standardise laboratory standard operating procedures to
ensure comparability of individual patient datasets.
However, if successful meta-analysis of multiple early-
phase studies is to be carried out in the future, this re-
view makes clear that development of a core outcome
set would also be desirable. This would provide a mini-
mum set of clearly defined outcomes to be reported in
each study [5]. The core outcome set would not be ex-
haustive and trialists would have the opportunity to
supplement it with any other outcomes of interest to
them in any given trial. However, agreement on a mean-
ingful core outcome set would make it easier for the re-
sults of trials to be compared, contrasted and combined
in systematic reviews, ultimately facilitating understand-
ing and accelerating improvement of treatment strat-
egies for patients with TB.
Recommendations
Pending development of, and agreement on, such a core
outcome set, our review suggests some interim recom-
mendations for reporting of future phase II studies of
pulmonary tuberculosis.
Sampling scheme
We suggest that the sampling scheme should be clearly
described, including information about the number and
type of samples taken, in particular whether the samples
were single or replicated, and the timing of sample col-
lection. The proportion of samples missing due to con-
tamination, failure to obtain or to produce a sample
should also be reported. Whatever analysis is performed,
summary results of bacteriological data at each time-
point should also be reported, if necessary in a supple-
ment to the study report.
Microbiological methods
Additionally, microbiological methods should be clearly
described, particularly the use of solid and liquid media
and the specific type or system used. It should always be
possible to disaggregate results for solid and liquid
media in study reports. Studies should also report per-
centages of cultures negative at the time points of inter-
est and use a consistent, explicit definition of culture
conversion. We recommend that this should be defined
as the time-point at which the first negative culture in a
series of negative cultures extending to the end of the
sampling period occurs. The major advantage of priori-
tising culture conversion as the endpoint of interest is
that it is a defined event rather than a continuing state
of positivity and better suited to time-to-event analysis,
which would facilitate comparison of results across stud-
ies with different sampling designs.
Measures of variability
Where quantitative bacteriological data are reported,
measures of variability of the measurements, preferably
the standard deviation, should always be reported. With
the exception of 2-month culture positivity, which has
support as a surrogate endpoint from meta-analyses and
regulators [1], serial bacteriological measurements should
be analysed using statistical approaches that provide esti-
mates of effect independent of the particular time-points
selected for the sampling scheme. This is particularly
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important as culture conversion rates at 2 months rise
with improving efficacy of regimens, reaching near-
universal culture conversion at this time point. Statistical
modelling approaches to quantitative bacteriology and
time-to-event methods are suitable for this purpose and
would facilitate combination of data from different studies
across a range of regimens with possibly widely varying
efficacies.
Individual participant data
Finally, due to the diversity of possible analytical ap-
proaches and the standard of reporting observed, routine
availability of individual patient datasets for the purposes
of meta-analysis is desirable where study reports and
supplementary information do not contain the data ne-
cessary to define relevant endpoints to similar defini-
tions across studies.
Our review suggests that simple measures could greatly
improve the quality of reporting of phase II outcomes but
also points to the need to develop a core outcome set for
early phase trials in TB which could secure more wide-
spread agreement on outcomes amongst trialists and reg-
ulators. Such an approach, alongside other harmonisation
initiatives in laboratory methods and data recording, could
greatly improve the informativeness of systematic reviews
in this area, enabling more confident prioritisation of
regimens for evaluation in phase III trials on the basis of
phase II results.
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